122 related articles for article (PubMed ID: 16880247)
1. Pegylated liposomal doxorubicin consolidation therapy.
Hamm W
Oncologist; 2006; 11(7):855; author reply 855-6. PubMed ID: 16880247
[No Abstract] [Full Text] [Related]
2. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
Collins Y; Lele S
J Natl Med Assoc; 2005 Oct; 97(10):1414-6. PubMed ID: 16353663
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.
Tripodi E; Cormio G; De Giorgi U; Valabrega G; Rubino D; Lepori S; Maltese G; Sabatucci I; Lorusso D
Int J Gynecol Cancer; 2019 Jan; 29(1):153-157. PubMed ID: 30640698
[No Abstract] [Full Text] [Related]
4. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study.
Rabinovich A; Ramanakumar AV; Lau S; Gotlieb WH
Acta Obstet Gynecol Scand; 2015 Jul; 94(7):776-780. PubMed ID: 25923364
[TBL] [Abstract][Full Text] [Related]
5. [Ovarian carcinoma. Residual therapy with pegylated liposomal doxorubicin?].
Musch A
Med Monatsschr Pharm; 2005 Dec; 28(12):453-5. PubMed ID: 16389880
[No Abstract] [Full Text] [Related]
6. Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?
Randon G; Nicoletto MO; Milite N; Muggia F; Conte P
Oncologist; 2014 Apr; 19(4):429. PubMed ID: 24668330
[TBL] [Abstract][Full Text] [Related]
7. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
8. Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin.
Kasprowicz NS; Fotopoulou C; Oskay-Ozcelik G; El KK; Boehmer D; Sehouli J
Anticancer Res; 2008; 28(3B):1943-6. PubMed ID: 18630485
[TBL] [Abstract][Full Text] [Related]
9. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Kubeček O; Bláha M; Diaz-Garcia D; Filip S
Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
Lyseng-Williamson KA; Duggan ST; Keating GM
BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
[TBL] [Abstract][Full Text] [Related]
11. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
13. [Pegylated liposomal doxorubicin in ovarian cancer treatment].
Nowak-Markwitz E
Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.
Markman M
Expert Opin Pharmacother; 2006 Aug; 7(11):1469-74. PubMed ID: 16859430
[TBL] [Abstract][Full Text] [Related]
15. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
17. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
[TBL] [Abstract][Full Text] [Related]
18. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Pegylated Liposomal Doxorubicin-Based Chemotherapy of AIDS-Related Kaposi's Sarcoma: A Meta-Analysis.
Liu R; Zhou J; Yang S; Zhang Z
Am J Ther; 2018; 25(6):e719-e721. PubMed ID: 29509553
[No Abstract] [Full Text] [Related]
[Next] [New Search]